{"schema_version":"secwatch.filing_event.v1","accession":"0001730430-26-000031","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2026-07-28T11:33:48+00:00","discovered_at":"2026-07-28T11:35:00.300395+00:00","generated_at":"2026-07-28T11:35:05.442529+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kiniksa Q2 ARCALYST revenue $243.6M (+55% YoY); raises FY2026 guidance to $980-995M","bullets":["ARCALYST net product revenue $243.6M in Q2 2026, ~55% YoY growth; ~21% of 14,000 multiple-recurrence patients on therapy.","2026 ARCALYST net revenue guidance raised to $980-995M from prior $930-945M.","Net income $25.4M vs $17.8M in Q2 2025; cash $525.9M, no debt.","KPL-387 Phase 2 data: median time to treatment response 4.0 days at 300 mg SC monthly; Phase 3 PASTORALE enrolling.","KPL-1161 preclinical; Phase 1 expected by end of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001730430-26-000031","json":"https://secwatch.observer/filing/0001730430-26-000031.json","markdown":"https://secwatch.observer/filing/0001730430-26-000031.md","text":"https://secwatch.observer/filing/0001730430-26-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000173043026000031/0001730430-26-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000173043026000031/knsa-20260728x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-28T11:35:05.442529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}